



PATENT
Customer No. 22,852
Attorney Docket No. 08505.0020-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Jenkins, Peter James et al.)	Group Art Unit: 1623
)	
Application No.: 10/776,188)	Examiner: E. Peselev
)	
Filed: February 12, 2004)	
)	
For: PREPARATION AND DIABETIC)	Confirmation No.: 3089
USE OF GIBBERELLINS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination in the above-referenced application. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Copies of the listed non-patent literature documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine

that the cited documents do not constitute "prior art" under United States law,
Applicants reserve the right to present to the office the relevant facts and law regarding
the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the
patentability of the disclosed invention over the listed documents, should one or more of
the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 9, 2005

By: 
Gretchen S. Peterson
Reg. No. 57,404



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	1	of	2	Application Number	10/776,188
				Filing Date	February 12, 2004
				First Named Inventor	Jenkins, Peter James
				Art Unit	1623
				Examiner Name	E. Peselev
				Attorney Docket Number	08505.0020-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Children's Medical Center at the University of Virginia, <i>Pediatric Pharmacotherapy</i> , 2:1-4 (1996).	
		Express Scripts, Inc., http://www.drugdigest.org/DD/PrintablePages/Comparisons/1,20038,8-21,00.html , printed on 03/08/2005.	
		"Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications," World Health Org., Dept. of Noncommunicable Disease Surveillance, Geneva 21-22 (1999).	
		Cardinal, et al., "Increased Susceptibility to Streptozotocin-Induced β -Cell Apoptosis and Delayed Autoimmune Diabetes in Alkylpurine-DNA-N-Glycosylase-Deficient Mice," <i>Molecular and Cellular Biology</i> , 21:5605-5613 (2001).	
		Ramasamy, et al., "Protein Kinase C and the Sub-Sensitivity and Sub-Reactivity of the Diabetic Rat Prostate Gland to Noradrenaline," <i>European Journal of Pharmacology</i> , 434:151-161 (2002).	
		Laposata, M., <i>SI Unit Conversion Guide</i> , Boston:NEJM Books, 81-83.	
		Murray, et al., "Effect of Meals and Posture on Concentration of Substances in Blood," <i>Harper's Biochemistry</i> , 24 th Ed., p. 830-832.	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/776,188	
			Filing Date	February 12, 2004	
			First Named Inventor	Jenkins, Peter James	
			Art Unit	1623	
			Examiner Name	E. Peselev	
Sheet	2	of	2	Attorney Docket Number	08505.0020-00000

NON PATENT LITERATURE DOCUMENTS			
		Dorland's Illustrated Medical Dictionary, 25 th Ed., Philadelphia:W. B. Saunders, 1673.	
		Sweetman, S.C. (Ed.), "Antidiabetics," Martindale, The Complete Drug Reference, 33 rd Ed., London:Pharmaceutical Press, 315-316.	
		"Glucophage", Glucolet Endcaps 1561 (1996).	
		MIMS Annual, "Hypoglycaemic Agents," 612, 614-618, 620 (2003).	
		Chen et al., "Duration of Streptozotocin-Induced Diabetes Differentially Affects p38-Mitogen-Activated Protein Kinase (MAPK) Phosphorylation in Renal and Vascular Dysfunction" Cardiovascular Diabetology 4:3 (2005). ABSTRACT.	
		Heilbron, I.M. (Ed.), Dictionary of Organic Compounds 6 th ed, London:Chapman & Hall, 2741-2747 (1996).	
		Rolandsson, et al., "Streptozotocin Induced Diabetes in Minipig: A Case Report of a Possible Model for Type 1 Diabetes" Autoimmunity 35:261-264 (2002). ABSTRACT.	
		Loudon, M. Organic Chemistry, 3 rd Ed. Redwood City, CA: Benjamin/Cummings Publishing Co., Inc., 131, 739 (1995).	
		March, J., Advanced Organic Chemistry, 4 th Ed. New York: J. Wiley and Sons, 423 (1992).	
		Roberts, J. et al., Basic Principles of Organic Chemistry, New York: W. A. Benjamin Co., 148 (1964).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.